查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750859

干癣药物市场规模、份额、趋势分析报告：按类别、治疗、给药途径、分销管道、地区、细分市场预测，2025-2030 年

Psoriasis Drugs Market Size, Share & Trends Analysis Report By Class, By Treatment (Topicals, Systemic, Biologics), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

干癣药物市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球干癣药物市场规模预计到2030年将达到391.1亿美元，预计2025年至2030年期间的复合年增长率为10.94%。

人们对该疾病的认识不断提高、生物製药报销策略的增加以及先进的诊断和技术工具可能会增加干癣药物的采用。

此外，不断扩大的干癣患者群体预计将推动其成长前景。干癣的确切致病因素尚待确定，但某些遗传和环境因素可能诱发其发病。大多数现有治疗方法旨在透过抑制角质形成细胞的过度增殖来减缓疾病的进展。

干癣分为五种类型：斑块、斑块状、逆性、脓疱型、红皮症型。这些类型根据病变部位和特征而有所不同。红皮病干癣最为罕见，而斑块干癣则是全球最常见的干癣类型。

近年来，干癣的盛行率在各地区呈现逐渐上升趋势。这种上升可能源自于遗传、环境因素以及生活方式的改变。盛行率的上升也可能与患者对疾病控制治疗的反应性降低和抗药性发展有关。

干癣药物市场报告重点

  • 肿瘤坏死因子抑制剂将占据市场主导地位，到 2024 年将占 40.88% 的份额。
  • 生物製药领域在 2024 年占据了 46.38% 的市场份额，这得益于其对与干癣相关的特定免疫途径的高度选择性，与传统药物相比，其疾病控制效果显着改善。
  • 预计在预测期内局部用药领域将实现显着的成长率。
  • 肠外药物领域将占据市场主导地位，到 2024 年将占 41.58% 的份额。
  • 到 2024 年，医院药房部门将占据干癣药物行业的主要份额。
  • 2024年北美干癣药物市场占据主导地位，占全球份额的38.65%。

目录

第一章调查方法与范围

第二章执行摘要

第三章干癣药物市场变数、趋势与范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章干癣药物市场：按类别的业务分析

  • 2025 年及 2030 年各类别市场占有率
  • 班级细分仪表板
  • 市场规模、预测与趋势分析（按类别，2018-2030 年）
  • 肿瘤坏死因子抑制剂
  • 白细胞介素抑制剂
  • 维生素 D 类似物
  • 皮质类固醇
  • 其他的

第五章干癣药物市场：依疗法进行的商业分析

  • 2025 年及 2030 年各疗法市场占有率
  • 治疗细分细分仪表板
  • 市场规模、预测与趋势分析（按治疗，2018-2030 年）
  • 外用药物
  • 系统性
  • 生物製药

第六章干癣药物市场：依给药途径进行的业务分析

  • 2025年及2030年市场占有率
  • 管理路线细分仪表板
  • 按管理路线分類的市场规模、预测和趋势分析（2018-2030 年）
  • 口服
  • 肠外
  • 外用

第七章干癣药物市场：分销通路业务分析

  • 2025 年和 2030 年按分销管道分類的市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 其他药局

第八章干癣药物市场：按地区分類的估计和趋势分析

  • 2025年及2030年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Eli Lilly and Company
    • AstraZeneca
    • Celgene Corporation
    • UCB SA
    • Merck
    • Boehringer Ingelheim International GmbH
Product Code: GVR-1-68038-662-2

Psoriasis Drugs Market Growth & Trends:

The global psoriasis drugs market size is estimated to reach USD 39.11 billion by 2030, registering to grow at a CAGR of 10.94% from 2025 to 2030 according to a new report by Grand View Research, Inc. Rising disease awareness, an increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, the expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping the hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of the site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

The incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. The rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Psoriasis Drugs Market Report Highlights:

  • Tumor necrosis factor inhibitors dominated the market and accounted for a share of 40.88% in 2024 as they effectively target the inflammatory pathways crucial to the disease, resulting in major enhancements.
  • The biologics segment dominated the market in 2024 with a share of 46.38% as they are highly selective to certain immune pathways in connection to psoriasis and massive improvements in disease management compared to traditional medicines.
  • The topical segment is expected to register a significant growth rate over the forecast period.
  • The parenteral segment dominated the market, accounting for a 41.58% share in 2024.
  • The hospital pharmacies segment accounted for a leading share of the psoriasis drugs industry in 2024.
  • North America psoriasis drugs market held a leading market position in 2024, accounting for 38.65% of the global share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Class
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Psoriasis Drug Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Psoriasis Drug Market: Class Business Analysis

  • 4.1. Class Market Share, 2025 & 2030
  • 4.2. Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Class, 2018 to 2030 (USD Million)
  • 4.4. Tumor Necrosos Factor Inhibitors
    • 4.4.1. Tumor Necrosos Factor Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. Interleukin Inhibitors
    • 4.5.1. Interleukin Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. Vitamin D Analogues
    • 4.6.1. Vitamin D Analogues Market, 2018 - 2030 (USD Million)
  • 4.7. Corticosteroids
    • 4.7.1. Corticosteroids Market, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Other Class Market, 2018 - 2030 (USD Million)

Chapter 5. Psoriasis Drug Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2025 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Topicals
    • 5.4.1. Topicals Market, 2018 - 2030 (USD Million)
  • 5.5. Systemic
    • 5.5.1. Systemic Market, 2018 - 2030 (USD Million)
  • 5.6. Biologics
    • 5.6.1. Biologics Market, 2018 - 2030 (USD Million)

Chapter 6. Psoriasis Drug Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.5. Parental
    • 6.5.1. Parental Market, 2018 - 2030 (USD Million)
  • 6.6. Topical
    • 6.6.1. Tropical Market, 2018 - 2030 (USD Million)

Chapter 7. Psoriasis Drug Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Other Pharmacies
    • 7.6.1. Others Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Psoriasis Drug Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Psoriasis Drug Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Psoriasis Drug Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Psoriasis Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Amgen Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Johnson & Johnson Services, Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Novartis AG
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Eli Lilly and Company
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AstraZeneca
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Celgene Corporation
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. UCB S.A.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Merck
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Boehringer Ingelheim International GmbH
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Psoriasis market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 5 Global Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 6 Global Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7 Global Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 North America Psoriasis market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 10 North America Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 11 North America Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 North America Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 14 U.S. Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 15 U.S. Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 U.S. Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 18 Canada Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 Canada Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20 Canada Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21 Mexico Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 22 Mexico Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 Mexico Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Mexico Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 Europe Psoriasis market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 27 Europe Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 28 Europe Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29 Europe Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 UK Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 31 UK Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 UK Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 UK Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Germany Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 35 Germany Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Germany Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Germany Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38 France Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 39 France Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 France Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 France Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42 Italy Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 43 Italy Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Italy Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45 Italy Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46 Spain Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 47 Spain Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Spain Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Spain Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Norway Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 51 Norway Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 52 Norway Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53 Norway Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Denmark Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 55 Denmark Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 56 Denmark Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 Denmark Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58 Sweden Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 59 Sweden Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Sweden Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Sweden Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Psoriasis market, by country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67 Japan Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 68 Japan Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 69 Japan Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Japan Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71 China Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 72 China Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 China Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74 China Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 India Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 76 India Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 77 India Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 India Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Australia Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 80 Australia Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 81 Australia Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Australia Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83 South Korea Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 84 South Korea Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 85 South Korea Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 South Korea Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87 Thailand Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 88 Thailand Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Thailand Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Thailand Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Latin America Psoriasis market, by country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 93 Latin America Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 94 Latin America Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95 Latin America Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96 Brazil Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 97 Brazil Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 98 Brazil Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99 Brazil Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100 Argentina Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 101 Argentina Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 102 Argentina Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 Argentina Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Psoriasis market, by country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109 South Africa Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 110 South Africa Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 111 South Africa Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 112 South Africa Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117 UAE Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 118 UAE Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 119 UAE Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 120 UAE Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Psoriasis market, by class, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Psoriasis market, by treatment, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Psoriasis market, by route of administration, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Psoriasis market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Psoriasis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Psoriasis market dynamics
  • Fig. 12 Psoriasis market: Porter's five forces analysis
  • Fig. 13 Psoriasis market: PESTLE analysis
  • Fig. 14 Class market, 2018 - 2030 (USD Million)
  • Fig. 15 Tumor Necrosis Inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 16 Interleukin Inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 17 Vitamin D Analogues market, 2018 - 2030 (USD Million)
  • Fig. 18 Corticosteroids market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Treatment market, 2018 - 2030 (USD Million)
  • Fig. 21 Topicals market, 2018 - 2030 (USD Million)
  • Fig. 22 Systemic market, 2018 - 2030 (USD Million)
  • Fig. 23 Biologics market, 2018 - 2030 (USD Million)
  • Fig. 24 Route of Administration market, 2018 - 2030 (USD Million)
  • Fig. 25 Oral market, 2018 - 2030 (USD Million)
  • Fig. 26 Parenteral market, 2018 - 2030 (USD Million)
  • Fig. 27 Topical market, 2018 - 2030 (USD Million)
  • Fig. 28 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 29 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 31 Other Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 32 Psoriasis market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin America Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework